These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27698913)

  • 1. Pretreatment TG/HDL-C Ratio Is Superior to Triacylglycerol Level as an Independent Prognostic Factor for the Survival of Triple Negative Breast Cancer Patients.
    Dai D; Chen B; Wang B; Tang H; Li X; Zhao Z; Li X; Xie X; Wei W
    J Cancer; 2016; 7(12):1747-1754. PubMed ID: 27698913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
    Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
    PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs.
    Fan Y; Ding X; Wang J; Ma F; Yuan P; Li Q; Zhang P; Xu B
    Int J Biol Markers; 2015 May; 30(2):e200-7. PubMed ID: 25953090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer.
    Liu J; Shi Z; Bai Y; Liu L; Cheng K
    Cancer Manag Res; 2019; 11():4471-4480. PubMed ID: 31191009
    [No Abstract]   [Full Text] [Related]  

  • 5. Pretreatment lymphocyte to monocyte ratio as a predictor of prognosis in patients with early-stage triple-negative breast cancer.
    He J; Lv P; Yang X; Chen Y; Liu C; Qiu X
    Tumour Biol; 2016 Jul; 37(7):9037-43. PubMed ID: 26762408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinogen/Albumin Ratio (FAR) in Patients with Triple Negative Breast Cancer and Its Relationship with Epidermal Growth Factor Receptor Expression.
    Gao W; Li M; Zhang Y
    Onco Targets Ther; 2021; 14():5403-5415. PubMed ID: 34908845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.
    Dai D; Chen B; Tang H; Wang B; Zhao Z; Xie X; Wei W
    PLoS One; 2016; 11(8):e0161902. PubMed ID: 27561099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer.
    Ren K; Yin Y; He F; Shao Y; Wang S
    Cancer Manag Res; 2018; 10():4891-4898. PubMed ID: 30425580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Usefulness of the Pretreatment Neutrophil/Lymphocyte Ratio as a Predictor of the 5-Year Survival in Stage 1-3 Triple Negative Breast Cancer Patients.
    Azab B; Amundson JR; Cioci A; Stuart H; Yakoub D; Avisar E; Moffat F; Livingstone AS; Franceschi D
    Breast Care (Basel); 2021 Feb; 16(1):43-49. PubMed ID: 33716631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.
    Chen H; Wu S; Hu J; Zhang K; Hu K; Lu Y; He J; Pan T; Chen Y
    J Oncol; 2021; 2021():6641421. PubMed ID: 34054955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer.
    Li X; Tang H; Wang J; Xie X; Liu P; Kong Y; Ye F; Shuang Z; Xie Z; Xie X
    Breast; 2017 Apr; 32():1-6. PubMed ID: 27939967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Short-term Prognostic Value of the Triglyceride-to-high-density Lipoprotein Cholesterol Ratio in Acute Ischemic Stroke.
    Deng QW; Li S; Wang H; Lei L; Zhang HQ; Gu ZT; Xing FL; Yan FL
    Aging Dis; 2018 Jun; 9(3):498-506. PubMed ID: 29896437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.
    Zhang L; Hao C; Dong G; Tong Z
    Breast Care (Basel); 2012 Feb; 7(1):13-17. PubMed ID: 22553467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.
    Wu Q; Ma G; Deng Y; Luo W; Zhao Y; Li W; Zhou Q
    Front Oncol; 2019; 9():1068. PubMed ID: 31681601
    [No Abstract]   [Full Text] [Related]  

  • 15. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma.
    Jiang SS; Weng DS; Jiang L; Zhang YJ; Pan K; Pan QZ; Chen CL; Zhao JJ; Zhang XF; Zhang HX; Tang Y; Zhou ZQ; Chen MS; Xia JC
    J Cancer; 2016; 7(6):626-32. PubMed ID: 27076843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment Hematocrit Is Superior to Hemoglobin as a Prognostic Factor for Triple Negative Breast Cancer.
    Chen B; Dai D; Tang H; Ai X; Chen X; Zhang X; Li Z; Xie X
    PLoS One; 2016; 11(11):e0165133. PubMed ID: 27851755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Significance of the Fibrinogen-to-Albumin Ratio in Patients With Triple-Negative Breast Cancer: A Retrospective Study.
    Yang Q; Liang D; Yu Y; Lv F
    Front Surg; 2022; 9():916298. PubMed ID: 35774393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.
    Eralp Y; Kılıç L; Alço G; Başaran G; Doğan M; Dinçol D; Demirci S; İçli F; Onur H; Saip P; Haydaroğlu A
    J Breast Health; 2014 Oct; 10(4):209-215. PubMed ID: 28331673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.